Boots OTC divestiture
This article was originally published in The Tan Sheet
Boots Group has provided a "memorandum of information" on its consumer unit, Boots Healthcare International, to parties who are "seriously interested" in purchasing the division, the firm said. The divestiture of the unit, which includes Clearasil skin care, Nurofen (ibuprofen) and Strepsils lozenges, is on track for completion by March 2006. Plans for the sale were announced in May (1"The Tan Sheet" May 30, 2005, p. 7)...
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.